Clinical trials: Influenza Human
Influenza
Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.
- Trial name
- NCT00742885
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza
The purpose of this study is: to assess clinical efficiency of Ergoferon for treatment of influenza to assess safety of Ergoferon for treatment of influenza to compare efficiency of Ergoferon and Tamiflu for treatment of influenza
- Trial name
- NCT01804946
- Testing
- Ergoferon, Oseltamivir
- Where
- 8 sites in Russia
- Volunteers
- 161 people
- Sponsor
- Materia Medica Holding
Influenza
Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years
This randomized, open-label, single-site study at Saint Louis University will enroll approximately 40 subjects who are healthy, 18 to 49 years old.
- Trial name
- NCT03101462
- Testing
- Inactivated Influenza Vaccine, Live Attenuated Influenza Vaccine
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
The primary objectives of this study were: To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (<) 36 months of age and 3 to <9 years of age, and in adults 18 to…
- Trial name
- GRC90 (NCT03617523)
- Testing
- Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Seasonal Influenza
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
This study will evaluate the safety and immunogenicity in healthy children and adolescents after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.
- Trial name
- NCT01209780
- Testing
- TIV, TIVf, Comparator TIV
- Where
- 13 sites in Colombia, Mexico and 2 more
- Volunteers
- 3,116 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Effect of Oseltamivir on Cognitive Function in Subjects With Influenza
This study has been designed to determine if subjects treated with oseltamivir in addition to standard of care treatment for influenza demonstrate a greater improvement in attention / working memory / processing speed / mood as…
- Trial name
- FOCUS (NCT01249833)
- Testing
- Oseltamivir
- Where
- 16 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Trial Management Group Inc.
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' Fluarix vaccine in children who have previously been vaccinated with two doses of Pandemrix at the age of…
- Trial name
- NCT01196026
- Testing
- Fluarix™, Havrix™ Junior
- Where
- 7 sites in Netherlands, Sweden
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A H3N2
Study Examining PrEP-001 in Healthy Subjects
Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.
- Trial name
- NCT03220048
- Testing
- PrEP-001
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hvivo
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Influenza, Influenza, Human
Revaccination With Influenza Vaccine GSK1247446A
The protocol is designed to demonstrate the safety of influenza vaccine GSK1247446A after revaccination.
- Trial name
- NCT00545025
- Testing
- Influenza Vaccine GSK1247446A, Fluarix™
- Where
- Belgium
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Influenza, Respiratory Syncytial Virus Infections
Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
This study evaluates a single use point of care diagnostic test in the diagnosis of influenza and other respiratory viral infections in adults. Participants will have a sample taken from their nose using a swab.
- Conditions
- Human Influenza, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Enterovirus Infections
- Trial name
- SIMPLIFI (NCT04431050)
- Testing
- Point of care testing of respiratory viruses.
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' influenza vaccine in children aged 3 to 17 years.
- Trial name
- NCT01379937
- Testing
- Influenza vaccine GSK1562902A Formulation 1, Influenza vaccine GSK1562902A Formulation 2, Havrix™
- Where
- 2 sites in Philippines
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Children younger than 5 years of age are at high risk for severe influenza disease (flu) and hospitalization due to flu. Scientists are in the process of re-evaluating the dosing initially based on whole virus vaccines to improve…
- Trial name
- NCT00778895
- Testing
- GSK Biologicals' influenza vaccine GSK1557482A, Vaxigrip
- Where
- 18 sites in Canada
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate an Influenza Vaccine Candidate
The purpose of this study is to evaluate the immune response and safety of influenza vaccine candidate with or without adjuvant compared to Fluarix™ administered intramuscularly in elderly aged 60 years old and above.
- Trial name
- NCT00321373
- Testing
- Candidate Influenza Vaccine GSK1247446A - 2 different formulations, FluarixTM
- Where
- 17 sites in Finland, Greece
- Volunteers
- 1,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2009 - 2010 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT00929331
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
This partially randomized, multi-center parallel-group study will evaluate the safety, pharmacokinetics and the effect on viral load and viral shedding of Tamiflu (Oseltamivir) in patients with influenza.
- Trial name
- NCT01050257
- Testing
- Oseltamivir IV, Oseltamivir Oral
- Where
- 96 sites in United States, Denmark and 7 more
- Volunteers
- 118 people
- Sponsor
- Hoffmann-La Roche
Influenza
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
The aim of the study was to assess the immunogenicity and safety of Fluzone Quadrivalent influenza vaccine Southern Hemisphere (SH) 2015 formulation in participants aged 18 to 60 years as well as in participants 61 years or…
- Trial name
- NCT03546192
- Testing
- Fluzone Quadrivalent Influenza Vaccine
- Where
- 3 sites in Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company